Short-Course Glecaprevir/Pibrentasvir Plus Ezetimibe Prevents HCV Transmission During Transplantation From HCV-Infected Donors

November 8-12, 2019; Boston, Massachusetts
This small study showed that a short preemptive course of GLE/PIB + EZE given pre- and post-transplant prevented HCV transmission in all HCV-uninfected patients who received organs from HCV-infected donors.
Format: Microsoft PowerPoint (.ppt)
File Size: 191 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Stefan Zeuzem, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Tarik Asselah: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Tarik Asselah, MD, PhD Released: July 20, 2021

CCO slideset: key viral hepatitis studies EASL 2021, including treatment of HDV, HBV, HCV in in adults and children, linking patients to care, HBV cure, and more

Tarik Asselah, MD, PhD Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 15, 2021

CCO downloadable slides from Dr. Tatyana Kushner providing insights on updated guidance for HCV screening and management in women of childbearing age

Tatyana Kushner, MD, MSCE Released: January 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue